{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:53:35Z","timestamp":1788951215221,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clinthera.2019.04.037","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T08:18:23Z","timestamp":1558599503000},"page":"1199-1212.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention"],"prefix":"10.1016","volume":"41","author":[{"given":"Miriam","family":"Saiz-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Belmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Caniego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Zubiaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"B\u00e1rcena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Romero-Palaci\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy R.","family":"Eugene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.04.037_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000338359","article-title":"Genetic determinations of variable responsiveness to clopidogrel and implications for neurointerventional procedures","volume":"1","author":"Colley","year":"2012","journal-title":"Interv Neurol"},{"key":"10.1016\/j.clinthera.2019.04.037_bib2","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clpt.2006.07.007","article-title":"Impact of P-glycoprotein on clopidogrel absorption","volume":"80","author":"Taubert","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2019.04.037_bib3","first-page":"29","article-title":"Pharmacokinetic profile of 14C-labeled clopidogrel","volume":"25","author":"Lins","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.clinthera.2019.04.037_bib4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/FPC.0b013e3283385420","article-title":"Clopidogrel pathway","volume":"20","author":"Sangkuhl","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.clinthera.2019.04.037_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.2281","article-title":"Paraoxonase-1 is a major determinant of clopidogrel efficacy","volume":"17","author":"Bouman","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2019.04.037_bib6","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bcp.12230","article-title":"Genetics of platelet inhibitor treatment","volume":"77","author":"Trenk","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.04.037_bib7","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","article-title":"Identification and biological activity of the active metabolite of clopidogrel","volume":"84","author":"Savi","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2019.04.037_bib8","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"3046","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2019.04.037_bib9","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/FPC.0b013e3282f1b2be","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10\u00a0+ 12G\/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients","volume":"172","author":"Giusti","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.clinthera.2019.04.037_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/hrt.2011.227652","article-title":"Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel","volume":"98","author":"Zabalza","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.clinthera.2019.04.037_bib11","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/eurheartj\/ehp041","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention","volume":"30","author":"Sibbing","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2019.04.037_bib12","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.04.037_bib13","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1538-7836.2009.03500.x","article-title":"The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome","volume":"7","author":"Fr\u00e9re","year":"2009","journal-title":"J\u00a0Thromb Haemost JTH"},{"key":"10.1016\/j.clinthera.2019.04.037_bib14","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/j.1538-7836.2010.03921.x","article-title":"Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy","volume":"8","author":"Sibbing","year":"2010","journal-title":"J\u00a0Thromb Haemost JTH"},{"key":"10.1016\/j.clinthera.2019.04.037_bib15","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ahj.2010.06.039","article-title":"Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events","volume":"160","author":"Tiroch","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2019.04.037_bib16","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","article-title":"Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement","volume":"121","author":"Sibbing","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2019.04.037_bib17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1538-7836.2011.04570.x","article-title":"The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients","volume":"10","author":"Li","year":"2012","journal-title":"J\u00a0Thromb Haemost JTH"},{"key":"10.1016\/j.clinthera.2019.04.037_bib18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"Scott","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2019.04.037_bib19","author":"Rakicevic"},{"key":"10.1016\/j.clinthera.2019.04.037_bib20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/cpt.1067","article-title":"Influence of CYP2C19 phenotype on the effect of clopidogrel in patients undergoing a percutaneous neurointervention procedure","volume":"105","author":"Saiz-Rodr\u00edguez","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2019.04.037_bib21","first-page":"215","article-title":"Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)","volume":"19","author":"Caudle","year":"2017","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"10.1016\/j.clinthera.2019.04.037_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/0269881119827959","article-title":"Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics","author":"Saiz-Rodr\u00edguez","year":"2019","journal-title":"J\u00a0Psychopharmacol (oxf)"},{"key":"10.1016\/j.clinthera.2019.04.037_bib23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","article-title":"No adjustments are needed for multiple comparisons","volume":"1","author":"Rothman","year":"1990","journal-title":"Epidemiol Camb Mass"},{"key":"10.1016\/j.clinthera.2019.04.037_bib24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/oxfordjournals.aje.a009532","article-title":"Describing data requires no adjustment for multiple comparisons: a reply from Savitz and Olshan","volume":"147","author":"Savitz","year":"1998","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clinthera.2019.04.037_bib25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/oxfordjournals.aje.a009530","article-title":"Invited commentary: Re: 'Multiple comparisons and related issues in the interpretation of epidemiologic data","volume":"147","author":"Thompson","year":"1998","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clinthera.2019.04.037_bib26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/asheducation-2007.1.114","article-title":"Aspirin and clopidogrel resistance","author":"Fitzgerald","year":"2007","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clinthera.2019.04.037_bib27","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction","volume":"109","author":"Matetzky","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2019.04.037_bib28","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2019.04.037_bib29","series-title":"CYP2C19 ultrarapid phenotype as a risk predictor of subsequent events during clopidogrel treatment in patients undergoing a percutaneous neurointervention","author":"Saiz-Rodr\u00edguez","year":"2019"},{"key":"10.1016\/j.clinthera.2019.04.037_bib30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3174\/ajnr.A4481","article-title":"Association between CYP2C19 polymorphisms and outcomes in cerebral endovascular therapy","volume":"37","author":"Lin","year":"2016","journal-title":"AJNR Am J Neuroradiol"},{"issue":"3","key":"10.1016\/j.clinthera.2019.04.037_bib31","first-page":"661","article-title":"Influence of CYP2C19 phenotype on\u00a0the effect of clopidogrel in patients undergoing a percutaneous\u00a0neurointervention procedure","volume":"105","author":"Saiz-Rodr\u00edguez","year":"2019","journal-title":"Clin\u00a0Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2019.04.037_bib32","doi-asserted-by":"crossref","first-page":"25478","DOI":"10.1038\/srep25478","article-title":"Association of CYP2C19 polymorphisms with the clinical efficacy of clopidogrel therapy in patients undergoing carotid artery stenting in Asia","volume":"6","author":"Zhu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2019.04.037_bib33","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/neuros\/nyx079","article-title":"A\u00a0multicenter cohort comparison study of the safety, efficacy, and cost of ticagrelor compared to clopidogrel in aneurysm flow diverter procedures","volume":"81","author":"Moore","year":"2017","journal-title":"Neurosurgery"},{"key":"10.1016\/j.clinthera.2019.04.037_bib34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/FPC.0b013e328333dafe","article-title":"Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation","volume":"20","author":"Harmsze","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.clinthera.2019.04.037_bib35","first-page":"243","article-title":"DoCYP2C19andABCB1gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients?","volume":"10","author":"Rytkin","year":"2017","journal-title":"Pharmacogenomics Pers Med"},{"key":"10.1016\/j.clinthera.2019.04.037_bib36","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/jcph.769","article-title":"The metabolism of clopidogrel: CYP2C19 is a minor pathway","volume":"56","author":"Ford","year":"2016","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.04.037_bib37","series-title":"CYP3A4*22 impairs the elimination of ticagrelor, but has no significant effect on the bioactivation of clopidogrel or prasugrel","author":"Holmberg","year":"2018"},{"key":"10.1016\/j.clinthera.2019.04.037_bib38","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.ajhg.2008.04.015","article-title":"Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis","volume":"82","author":"Zhu","year":"2008","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clinthera.2019.04.037_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0b013e32835aa8a2","article-title":"The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response","volume":"23","author":"Lewis","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.clinthera.2019.04.037_bib40","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.ijcard.2012.07.020","article-title":"Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction","volume":"167","author":"Verschuren","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinthera.2019.04.037_bib41","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/j.1476-5381.2012.01946.x","article-title":"The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in\u00a0vitro","volume":"166","author":"Ancrenaz","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2019.04.037_bib42","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11239-015-1264-9","article-title":"PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes","volume":"41","author":"Mega","year":"2016","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"82\u20138","key":"10.1016\/j.clinthera.2019.04.037_bib43","first-page":"S1","article-title":"No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting","volume":"5","author":"Jaitner","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.clinthera.2019.04.037_bib44","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00008571-200104000-00005","article-title":"MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity","volume":"11","author":"Ameyaw","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.clinthera.2019.04.037_bib45","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1067\/mcp.2001.117412","article-title":"Identification of functionally variant MDR1 alleles among European Americans and African Americans","volume":"70","author":"Kim","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2019.04.037_bib46","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1023\/A:1012244520615","article-title":"MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects","volume":"18","author":"Sakaeda","year":"2001","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2019.04.037_bib47","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1067\/mcp.2002.126177","article-title":"Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein","volume":"72","author":"Kurata","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2019.04.037_bib48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0304-3835(02)00232-X","article-title":"Basal expression of the multidrug resistance gene 1 (MDR-1) is associated with the TT genotype at the polymorphic site C3435T in mammary and ovarian carcinoma cell lines","volume":"185","author":"Sauer","year":"2002","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clinthera.2019.04.037_bib49","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.thromres.2011.01.012","article-title":"High on-clopidogrel platelet reactivity: genotyping can help to optimize antiplatelet treatment","volume":"128","author":"Szymezak","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.clinthera.2019.04.037_bib50","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4103\/0253-7613.186191","article-title":"Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults","volume":"48","author":"Sridharan","year":"2016","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.clinthera.2019.04.037_bib51","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.thromres.2007.01.012","article-title":"Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome","volume":"120","author":"Cuisset","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.clinthera.2019.04.037_bib52","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"7139","key":"10.1016\/j.clinthera.2019.04.037_bib53","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1136\/bmj.316.7139.1236","article-title":"What's wrong with Bonferroni adjustments","volume":"316","author":"Perneger","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2019.04.037_bib54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2288-2-8","article-title":"Do multiple outcome measures require p-value adjustment?","volume":"2","author":"Feise","year":"2002","journal-title":"BMC Med Res Methodol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819302401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819302401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:50:20Z","timestamp":1758963020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819302401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0149291819302401"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.04.037","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.04.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}